5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • IMmotion151: A randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Motzer, R. J.; Powles, T.; Atkins, M. B.; Escudier, B.; McDermott, D. F.; Suarez, C.; Bracarda, S.; Stadler, W. M.; Donskov, F.; Lee, J. L.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma
    Meeting Abstract

    Motzer, R. J.; Grunwald, V.; Hutson, T. E.; Porta, C.; Powles, T.; Eto, M.; Dutcus, C. E.; Baig, M. A.; Dutta, L.; Li, D.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • c15-153: Randomized phase IB/II study of enzalutamide with and without ribociclib in patients with metastatic castrate resistant, chemotherapy naive prostate cancer that retains RB expression
    Meeting Abstract

    Kelly, W. K.; Godwin, J. L.; Hoffman-Censits, J. H.; Knudsen, K. E.; De Leeuw, R.; Leiby, B. E.; Southwell, T.; Hubert, C.; Smith, D. C.; Chatta, G. S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs
    Meeting Abstract

    Morris, M. J.; Vogelzang, N. J.; Sartor, A. O.; Armour, A. A.; Messmann, R. A.; Groaning, M.; Robarts, A.; Tolcher, A. W.; Gordon, M. S.; Babiker, H. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT)
    Meeting Abstract

    McHugh, D. J.; Funt, S.; Silber, D.; Knezevic, A.; Patil, S.; O'Donnell, D.; Tsai, S.; Reuter, V. E.; Sheinfeld, J.; Carver, B. S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • EV-103 study: A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer
    Meeting Abstract

    Hoimes, C. J.; Petrylak, D. P.; Flaig, T. W.; Carret, A. S.; Melhem-Bertrandt, A.; Rosenberg, J. E.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Next generation sequencing of urothelial bladder cancer: Memorial Sloan Kettering Cancer Center experience in 454 patients
    Meeting Abstract

    Isharwal, S.; Audenet, F.; Drill, E. N.; Ostrovnaya, I.; Pietzak, E. J.; Al-Ahmadie, H.; Cha, E. K.; Donahue, T. F.; Teo, M. Y.; Funt, S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial
    Meeting Abstract

    George, D. J.; Hessel, C.; Halabi, S.; Sanford, B. L.; Michaelson, M. D.; Hahn, O. M.; Walsh, M. K.; Olencki, T.; Picus, J.; Small, E. J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Exploratory pharmacogenomic analysis
    Meeting Abstract

    George, D. J.; Martini, J. F.; Staehler, M. D.; Chang, Y. H.; Breza, J.; Patard, J. J.; Motzer, R. J.; Magheli, A.; Carteni, G.; Donskov, F.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Defining the DNA damage repair (DDR) genomic landscape of urothelial carcinoma of the bladder (UCB)
    Meeting Abstract

    Dason, S.; McPherson, V.; Teo, M. Y.; Isharwal, S.; Audenet, F.; Bagrodia, A.; Cha, E. K.; Berger, M. F.; Zehir, A.; Schultz, N.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save